The U.S. Department of Health and Human Services (HHS) announced Wednesday that it will temporarily allow compounding pharmacies to produce and dispense six unapproved peptides by prescription, bypassing standard FDA drug approval processes.
The policy, issued under the Trump administration, grants enforcement discretion to small compounding pharmacies for BPC-157, TB-500, epitalon, MOTS-c, KPV, and semax—substances promoted for uses ranging from wound healing to metabolic health. The HHS stated the move aims to shift consumers away from unregulated black-market sources, though the peptides remain unproven for safety and effectiveness under FDA standards.
Pharmacies must meet new requirements, including patient-specific prescriptions, traceable ingredients, and adverse event reporting—a shift from prior gray-market sales. The policy does not grant FDA approval or confirm clinical benefits, according to the agency’s statement.
Policy Details and Regulatory Context
The HHS policy directs the FDA not to take legal action against compounding pharmacies that produce the six peptides, despite their lack of FDA review. The agency cited patient safety as a rationale, arguing that regulated compounding pharmacies would provide a safer alternative to overseas suppliers and online "research-only" vendors.
FDA scientists opposed the move, warning in internal deliberations that the policy could undermine the agency’s authority to block unproven drugs. A July FDA advisory panel had voted in favor of expanded access through compounding pharmacies, but FDA staff scientists recommended against lifting restrictions, citing insufficient evidence.
The policy requires compounding pharmacies to:
- Certify ingredient identity and purity
- Report side effects (previously unmandated)
- Limit production to prescription orders
Promoted Uses and Scientific Uncertainty
The six peptides are marketed for diverse applications, though clinical evidence is limited:
- BPC-157 & TB-500: Promoted for wound healing and muscle repair; banned as doping agents by some sports organizations.
- Epitalon: Marketed for insomnia and longevity.
- MOTS-c: Claimed to support metabolic health.
- KPV: Advertised for wound healing.
- Semax: Used for migraine relief.
Wellness influencers and some clinicians have popularized these peptides, but the FDA has not evaluated their safety or efficacy. The HHS acknowledged the lack of clinical validation, stating the policy does not establish safety or effectiveness.
Reactions and Broader Implications
HHS Secretary Robert F. Kennedy Jr. has been a public advocate for peptides, stating he has used some himself. An HHS spokesperson framed the policy as part of a broader push for patient safety, arguing it would reduce reliance on unregulated sources.
Critics, including former FDA officials and public health advocates, argue the move circumvents rigorous drug approval processes. Dr. Peter Lurie, president of the Center for Science in the Public Interest, called the policy an example of the FDA "turning a blind eye" to unproven treatments.
The policy is temporary, with HHS indicating it is part of a larger regulatory review. Compounding pharmacies may face supply challenges, as the policy focuses on smaller producers rather than large-scale manufacturing.